Robert M. Forrester
Fondatore presso EQRx International, Inc.
Profilo
Robert M.
Forrester founded EQRx, Inc. in 2019, where he worked as Chief Experience Officer from 2019 to 2023.
Mr. Forrester also founded EQRx International, Inc., where he worked as Chief Experience Officer, Brixton Biosciences, Inc., where he worked as Director, and IDRx, Inc., where he worked as Director.
Mr. Forrester also currently works at Rhapsody Biologics, Inc., as Director, SevenOaks Biosystems LLC, as Director from 2014, Pillar Biosciences, Inc., as Independent Director from 2020, Affyimmune Therapeutics, Inc., as Director from 2022, Deciduous Therapeutics, Inc., as Independent Director from 2021, OnCusp Therapeutics6, as Independent Director from 2023, and Eyecool Therapeutics, Inc., as Director.
Mr. Forrester also formerly worked at CombinatoRx, Inc., as President & Chief Executive Officer from 2009 to 2010, Verastem, Inc., as President, Chief Executive Officer & Director from 2013 to 2019, Immunomedics, Inc., as Independent Director in 2017, Gelesis, Inc., as Director, Atlantic Healthcare Plc, as Director, CPEX Pharmaceuticals, Inc., as Director in 2010, Myrexis, Inc., as Independent Director from 2011 to 2013, MeesPierson, Inc., as Managing Director-Proprietary Investment Group from 1994 to 2000, MoMelan Technologies, Inc., as Director, Coley Pharmaceutical Group, Inc., as Senior VP-Finance & Corporate Development from 2000 to 2003, FORMA Therapeutics, Inc., as Chief Operating Officer from 2010 to 2011, Neuromed Pharmaceuticals Ltd., as Chief Operating Officer & Executive Vice President from 2004 to 2010, and Arthur Andersen LLP.
Mr. Forrester received his graduate degree from the University of Bristol and graduate degree from The University of Law Ltd.
Posizioni attive di Robert M. Forrester
| Società | Posizione | Inizio |
|---|---|---|
Rhapsody Biologics, Inc.
 Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | Direttore/Membro del Consiglio | - |
SevenOaks Biosystems LLC
 SevenOaks Biosystems LLC Medical SpecialtiesHealth Technology Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016. | Direttore/Membro del Consiglio | 01/09/2014 |
Pillar Biosciences, Inc.
 Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | Direttore/Membro del Consiglio | 06/10/2020 |
Deciduous Therapeutics, Inc.
 Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | 27/10/2021 |
EQRx International, Inc.
 EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | Fondatore | - |
IDRx, Inc.
 IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Fondatore | - |
Affyimmune Therapeutics, Inc.
 Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | Direttore/Membro del Consiglio | 29/09/2022 |
Brixton Biosciences, Inc.
 Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | Fondatore | - |
Eyecool Therapeutics, Inc.
 Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | Direttore/Membro del Consiglio | - |
| ░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Precedenti posizioni note di Robert M. Forrester
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Robert M. Forrester
| University of Bristol | Graduate Degree |
| The University of Law Ltd. | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MYREXIS, INC. | Finance |
| VERASTEM, INC. | Health Technology |
| EQRX, INC. | Health Technology |
| Aziende private | 20 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Atlantic Healthcare Plc
 Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Health Technology |
CPEX Pharmaceuticals, Inc.
 CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
| MeesPierson, Inc. | Finance |
Rhapsody Biologics, Inc.
Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | Health Technology |
MoMelan Technologies, Inc.
 MoMelan Technologies, Inc. Medical SpecialtiesHealth Technology MoMelan Technologies, Inc. operates as a developer of Epigraft a device to treat skin disorders by expanding the surface area of skin grafts. Epigraft is an unique medical device platform that enables optimized mechanical antilogous epidermal transplant. The company was founded by Sameer A Sabir and R. Rox Anderson in 2009 and is headquartered in Cambridge, MA. | Health Technology |
SevenOaks Biosystems LLC
SevenOaks Biosystems LLC Medical SpecialtiesHealth Technology Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016. | Health Technology |
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA. | Health Technology |
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | Commercial Services |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Health Technology |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | Health Technology |
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | Commercial Services |
OnCusp Therapeutics6
 OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | Commercial Services |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Robert M. Forrester